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Key Words: point-of-care, STI, Chlamydia, gonorrhea, trichomoniasis, HIV (Point of Care 2010;9: 36Y46) P oint-of-care (POC) tests are an important strategy to address the epidemic of sexually transmitted infections (STIs) in the United States, especially in adolescents. The burden of STIs in the United States is greatest in adolescents and young adults, and untreated women are at the greatest risk of sequelae, such as pelvic inflammatory disease, infertility, ectopic pregnancy, and chronic pelvic pain. In the usual STI testing scenario, the patient is tested and, if infection is suspected based on clinical findings, given presumptive treatment. However, if persons are not treated at the visit, there is often a delay between visit and treatment, and a substantial proportion may never receive follow-up at all. Clinicians must weigh the risk of delay and loss to follow-up against the risks of overtreatment and antibiotic resistance. In contrast, POC tests allow the clinician to provide immediate and confidential test results and treatment. In addition, POC test results constitute a teachable moment; that is, an opportunity to provide immediate feedback to the patient that may impact his/her risk behaviors. For these reasons, POC STI tests may be of great importance for the care of adolescents and young adults.
In this article, we will review the current literature describing POC STI tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and human immunodeficiency virus (HIV). We will include studies of test performance and their potential impact on treatment intervals and disease spread. In addition, we will discuss the World Health Organization (WHO)'s affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free, and delivered (ASSURED) criteria for judging POC tests. We will present theoretical and proposed pitfalls and solutions to implementing POC tests in clinical settings and their potential use in using nontraditional venues.
EVALUATION OF CURRENTLY AVAILABLE POC TESTS

Chlamydia Infection
In 2007, Chlamydia infection was the most frequently reported disease to the Centers for Disease Control and Prevention (CDC), with 1.18 million cases being reported. 1 Chlamydia infection is the most prevalent reportable STI among adolescents. Recent population surveys estimate that up to 4.7% of women and 3.7% of men aged 18 to 26 years are affected by Chlamydia infection. 2 In the United States, the estimated incidence in this age group is 1.9 million cases per year. 3 More than 90% of infections are asymptomatic, which points to the need for universal screening in this age group. Thus, it is not surprising that much of prior and current research efforts have been directed at developing a sensitive POC or rapid test for Chlamydia.
Various types of rapid tests for detecting C. trachomatis have been developed. Currently, these include the optical immunoassay (OIA) (Inverness [formerly BioStar], Princeton, NJ), Clearview Chlamydia (Inverness, Princeton, NJ), QuickVue (Quidel, San Diego, Calif ), and the new Chlamydia Rapid Test (CRT; Diagnostics for the Real World, Ltd, Cambridge, UK). The first 3 are cleared for clinical use by the US Food and Drug Administration (FDA), whereas the CRT is available in Europe. Two other tests, OneStep (CLIAwaived, Inc, San Diego, Calif ) and the Magnetic ImmunoChromatographic Test (MagnaBioSciences, Green Cross Medical Sciences Corp, San Diego, Calif ), have product information on their Web sites but have not yet been evaluated in the literature or achieved FDA clearance.
The BioStar OIA Chlaymdia test (Inverness, Princeton, NJ) is a cartridge-based OIA test. In a study by Pate et al 4 in 1998, 3 endocervical swabs were collected from 306 women aged 15 to 52 years attending an STI clinic in Alabama. The swabs were tested using the BioStar OIA Chlamydia test, cell culture, direct fluorescent antibody (DFA) assay (Syva MicroTrak; Syva Co, Palo Alto, Calif ), and polymerase chain reaction (PCR; Roche Amplicor C. trachomatis; Roche, Branchburg, NJ). A Chlamydia infection was defined as 2 or more positive test results. Based on this, 42 (13.7%) of 306 participants were positive for Chlamydia. Using this criterion, the BioStar Chlamydia test demonstrated a sensitivity of 73.8% and a specificity of 100%. 4 In addition, Bandea et al 5 evaluated the BioStar test at the CDC. They reported a sensitivity of 59.4% and a specificity of 98.4% from 261 adolescent girls compared with those using a nucleic acid amplification test (NAAT; Table 1 ). Because NAATs are now considered to be the criterion standard for diagnosis of Chlamydia infection, older studies comparing POCs with culture as the criterion standard might result in overestimation of the sensitivity because culture is considered to be 65% to 85% sensitive. Thus, a reported sensitivity of 73.8% when compared with that of culture might have a true sensitivity and expected performance for OIA of approximately 48% (i.e.; 73.8% of 65%) when compared with that using the NAAT. The BioStar test requires 20 minutes and 11 steps to complete the process. A positive result is a solid blue or purple circle reaction (of any intensity) that appears around the internal control dot. A negative result is when no blue or purple circle surrounds the internal control dot. It is not waived under the Clinical Laboratory Improvement Act (CLIA) and is graded as moderately complex. Clinical Laboratory Improvement ActYwaived tests are determined to be easy to use, have little risk of an incorrect result, and can be performed in a clinic or physician's office rather than in a laboratory.
The Clearview Chlamydia (Inverness) is another available test, called a single-reagent immunoassay test. Three published reports evaluated the Clearview Chlamydia test performance. In 1991, Stratton et al 6 compared Clearview with Chlamydia culture. Cervical swabs were collected from women attending an obstetrics/gynecology clinic. Of 648 cervical specimens, 40 were culture positive (6.2% prevalence) for Chlamydia. The Clearview Chlamydia detected 38 of the 40 cultures positive for Chlamydia, and an additional 12 were positive for Chlamydia using the Clearview Chlamydia and negative for Chlamydia using culture. Thus, Clearview Chlamydia had 95% sensitivity and 98% specificity, with positive and negative predictive values [NPVs] of 76% and 99.7%, respectively, compared with culture. The authors noted that the Clearview was less technically demanding than other chlamydial assays. In a similar study comparing Clearview with culture, 965 women aged 14 to 82 years who were attending gynecological clinics were included. 7 Culture was positive in 43 for Chlamydia (4.5% prevalence). In this study, Clearview was 79% sensitive and 99.6% specific, which was similar to the performance of a commercial laboratoryY based enzyme immunoassay (Chlamydiazyme; Abbott Laboratories, North Chicago, Ill) for detecting Chlamydia. As we described for BioStar, these sensitivities also represent overestimates because culture was used as the criterion standard instead of NAAT.
A more recent study by Yin et al 8 compared Clearview Chlamydia with a NAAT (PCR) test using cervical and vaginal swabs from 1497 women, with a mean age of 28 years, who were recruited from STI clinics. Three vaginal and 3 cervical swabs were collected from each participant. The Clearview Chlamydia test was done with the first vaginal and cervical swabs, and the results were read by 2 research staff members. The second and third vaginal and cervical swabs were used for PCR testing (Roche Amplicor C. trachomatis assay). Using cervical PCR results to define true infection, Chlamydia infection prevalence was 13.2% (197/1497 9 Rani et al 10 compared QuickVue with NAAT testing of endocervical specimens from high-and low-prevalence populations. One hundred women attending a genitourinary medicine clinic made up the high-prevalence participants, and 100 women attending a gynecology department at a hospital constituted the low-prevalence group. Two endocervical swabs were collected from each woman in both groups. For the high-prevalence 13 In summary, the 3 POC enzyme immunoassay tests for Chlamydia that are available in the United States are moderately complex to perform and demonstrate disappointing sensitivity (25%Y65%) compared with NAAT and are thus unlikely to be useful for clinical decision making. The CRT in use in the UK seems promising, and several new tests are in development.
Gonorrhea
Neisseria gonorrhoeae infection is one of the most prevalent sexually transmitted diseases in men and women. In 2007, there were 356,524 cases reported to the CDC. 14 Estimates of true incidence are approximately 700,000 new cases per year. The highest prevalence of gonorrhea is among 15-to 19-yearold African American females. Gonorrhea is less common than Chlamydia infection in adolescents, averaging approximately 0.42% in women and 0.44% in men in population studies of asymptomatic young adults aged 18 to 26 years. 2 As with Chlamydia, a substantial number of infections occur in asymptomatic women, and infection has serious sequelae for women (pelvic inflammatory disease, infertility, chronic pelvic pain, and ectopic pregnancy). Thus, annual screening is recommended. Laboratory methods to make the diagnosis include culture (requires stringent conditions), Gram stain (not very sensitive in women), or NAAT. Because culture performs very well in detecting gonorrhea, either culture or NAAT can be used for genital infections. 15 Point-of-care tests for gonorrhea that are in development include the currently marketed OIA (Inverness [formerly BioStar]) and 2 new products, the Program for Appropriate Technology in Health (PATH) GC-Check (PATH, Seattle, Wash) and OneStep (Cortez Diagnostics, Inc, Calabasas, Calif ).
The BioStar OIA gas chromatographic (GC) test was evaluated in a study by Benzaken et al. 16 Endocervical swabs were collected from 326 high-risk women, aged 18 to 55 years, at a STI clinic in Brazil. The prevalence of gonorrhea was 15% by culture. In comparison with culture, the BioStar GC test had a sensitivity of 60% (95% confidence interval [CI], 46.4%Y73.6%), a specificity of 89.9% (95% CI, 86.2%Y93.6%), a PPV of 55.6% (95% CI, 42.4%Y68.8%), and an NPV of 92.6% (95% CI, 89.5%Y95.7%; Table 2) .
A study comparing the OIA GC test with commercial culture media, with secondary confirmation testing by ligase chain reaction, reported that a total of 904 specimens were obtained from symptomatic patients at 4 clinical locations. Sensitivity and specificity for symptomatic male urine were 93.2% and 97.5%, respectively. Sensitivity and specificity for symptomatic female endocervical swabs were 70.7% and 99.4%, respectively. Overall, PPV and NPV for men were 94.0% and 97.2%, respectively, and for women were 90.6% and 97.24%, respectively. 17, 18 The BioStar GC test has 9 to 10 steps depending on if you are using female endocervical swabs or male urine specimens. It takes approximately 20 minutes to complete. A positive result is The PATH GC-Check is an immunochromatographic strip test (dipstick) that takes 15 to 20 minutes to perform. In a study by Alary et al, 20 samples from 1084 female sex workers in Berlin were tested using this POC method and compared with those using NAAT (Roche Amplicor C. trachomatis/N. gonorrhoeae PCR). The prevalence of gonorrhea among the women was 4.6%. In comparison with NAAT, the GC-Check was 70% sensitive and 97.2% specific and had a PPV of 54.7% and an NPV of 98.5% when using cervical swabs. When using vaginal swabs, PATH GC-Check was 54.1% sensitive and 98.2% specific (Table 2) .
To date, the only information available on the OneStep Strip Style Gonorrhea test (Cortez Diagnostics, Inc) is product literature found on the company's Web site. 21 The test can be performed on a male urethral or female vaginal swab. The manufacturer tested 150 female vaginal swabs and compared results with those of culture. The sensitivity of the test was 98.3%, and the specificity was 97.8%. The prevalence of gonorrhea in this population was 39.3%. This is unusual because vaginal swabs for gonorrhea culture have not been validated in the literature; thus, the true sensitivity of this assay may be less than reported (Table 2) . OneStep takes 10 to 20 minutes to read the results. It is a simple 3-step process that involves adding drops of diluents then dipping a test strip into the mixture. A negative result is when there is only 1 colored band on the control region. A positive result shows a pink band in addition to the control line. 21 In summary, the 3 POC tests for gonorrhea have a wide range of sensitivities (60%Y98%) but promising levels of specificity (90%Y98%). If a higher and more consistent sensitivity can be reached, these rapid gonorrhea tests could be used clinically in the future.
Trichomoniasis
Trichomoniasis is one of the most prevalent and often undetected STIs. Accurate prevalence and incidence data are harder to find because trichomoniasis is not a reportable STI. Weinstock et al 3 estimate that there were 7.4 million new cases of trichomoniasis in 2000, compared with 2.8 million new cases of Chlamydia infection among 15-to 24-year-olds in the United States. A recent cross-sectional study showed that in a population of adolescents and young adults in the United States, the prevalence of trichomoniasis (2.1%) is similar to that of Chlamydia infection (4.2%) and 6 times higher than that of gonorrhea (0.43%). 22 In addition, the usual testing method is direct microscopy of a saline preparation of vaginal secretions (wet mount), which has been shown to be approximately 50% sensitive compared with culture or NAAT. 23Y25 Although some women with trichomoniasis may develop vaginal symptoms, as is true for Chlamydia infection and gonorrhea, most cases of trichomoniasis occur in asymptomatic individuals. Because recent studies have linked trichomoniasis to HIV acquisition and shedding, there is a new urgency for better POC testing for trichomoniasis. 26 These new tests include XenoStrip, OSOM, and Affirm VPIII. 27 XenoStrip-Tv (Xenotope Diagnostics, Inc, San Antonio, Tex) is an immunochromatographic test device that detects T. vaginalis membrane proteins. Miller et al 28 tested vaginal swabs collected from women during a large STI project in Peru. They tested samples from 20 women with known positive culture results and 40 samples from women with negative culture results. When these previously frozen samples were tested with XenoStrip-Tv, it had 90% sensitivity and 92.5% specificity compared with culture (Table 3) . Furthermore, in a multicenter study by Kurth States. When it was available for use, it took up to 20 minutes to read the result and could detect the presence of 10 to 100 T. vaginalis in 0.5 mL of vaginal fluid (Table 3) . 28 OSOM TV Trichomonas Rapid Test (Genzyme Diagnostics, Cambridge, Mass) is also an immunochromatographic capillary flow (dipstick) assay that detects T. vaginalis membrane proteins. Huppert et al 30 Table 3 ).
Other studies have demonstrated the effectiveness of the OSOM test. In a 2007 study, Huppert et al 25 used vaginal swabs to test 330 sexually active females aged 14 to 21 years for trichomoniasis. The vaginal swabs were tested using wet mount, culture, OSOM, and NAAT (transcription-mediated amplification [TMA]). The prevalence of trichomoniasis in this population was 18.5% (61/330). Using latent class analysis, OSOM was shown to be 90% sensitive and 100% specific. 25 In addition, the sensitivities of OSOM (92.5%) and TMA (97.5%) were comparable with those in women who had vaginal symptoms.
In a follow-up to this study, Patullo et al, 31 performed 2 additional T. vaginalis tests for subjects who tested negative for infection using wet mount. The remaining wet mount saline was used to inoculate an InPouch TV culture, and the used wet mount swab was tested with OSOM. The most sensitive strategy to detect trichomoniasis using 2 tests was wet mount followed by OSOM, with a sensitivity of 86.4% (95% CI, 75.3%Y93.4%). OSOM detected T. vaginalis in 67% of true positive; and wet mount, negative cases. In addition, the likelihood of a positive OSOM test result increased with increasing time between specimen collection and testing. Therefore, the OSOM test can be delayed or performed on a used swab with no loss of sensitivity (Table 3) .
One study of OSOM in a low-prevalence population showed a surprisingly low sensitivity. Compared with wet mount examination, a total of 19 (2%) of 1009 women had T. vaginalis infection, and OSOM detected 18 of these cases. The one discrepant test was tested with NAAT (TMA) and had a negative result, for a resolved sensitivity and specificity of 94.7% and 100%, respectively (Table 3) . 32 The OSOM TV Rapid Test takes 5 steps to complete, and result can be read in 10 minutes. It contains an internal control that is shown by a red control line. A negative test result shows just the control line, and a positive test result shows the red control line plus a blue test line. It is CLIA waived. 33 Affirm VPIII Microbial Identification Test (Becton Dickinson, Sparks, Md) is a test that detects T. vaginalis, Candida sp, and Gardnerella vaginalis. It uses synthetic nucleic acid capture probes and color development detection probes complementary to unique genetic sequences of the target organisms and takes 45 minutes to achieve results. In a study by Briselden and Hillier, 34 5 vaginal swabs were collected from 176 women attending a STI clinic in Seattle, Wash. The swabs were cultured for G. vaginalis and T. vaginalis and were also tested with Gram stain, wet mount, and Affirm VP, an earlier version than the currently marketed Affirm VPIII. Trichomoniasis was found in 12 (7%) of 170 specimens tested by wet mount and in 15 specimens tested by culture (9%). The sensitivity of Affirm VP when compared with that of culture and/or wet mount was 83%, and the specificity was 100%. DeMeo et al 35 compared Affirm VP with wet mount and culture, resulting 615 women attending family planning clinics. Trichomonas was found in 95 (15.4%) of the 615 specimens. Compared with wet mount/culture, Affirm VP was 90.5% sensitive and 98% specific for trichomonas (Table 3) .
A more recent study by Brown et al 36 evaluated a newer version of the test, Affirm VPIII. Two vaginal swabs were collected from 425 symptomatic and asymptomatic women being seen for routine obstetrics and gynecology care. One swab was evaluated using wet mount and the other using the Affirm VPIII test. Trichomonas was found in 30 participants (7% of total) by Affirm VPIII and 23 (5% of total) by wet mount. Symptomatic participants were more likely than asymptomatic women to be positive by Affirm VPIII (23% vs 10%) and by a combination of Affirm VPIII and wet mount testing (15% vs 1%). In a study of 535 military women, Affirm VPIII was compared with clinical diagnosis only, and the prevalence of T. vaginalis was extremely low (1.5%; Table 3 ). 37 Neither of these 2 studies reported sensitivity or specificity of the Affirm VPIII. However, product literature compares Affirm VPIII with wet mount and culture for 852 patients. The sensitivity and specificity of Affirm VPIII compared with those of wet mount were 91.8% and 98.1%. Compared with culture, Affirm VPIII was 89.2% sensitive and 99.3% specific. 38 Affirm VPIII has not been compared directly with NAAT with detect trichomoniasis. As culture is found to be 80% to 90% sensitive compared with NAAT, the expected performance of Affirm VPIII would be less than that reported in the product literature. Although advertised as a POC test, the Affirm VPIII requires purchase of an analyzer and must be performed in a laboratory. It is considered a moderately complex test with numerous steps (at least 10) and requires 45 minutes for results. 38 In summary, both Affirm and OSOM seem to detect more T. vaginalis infections than wet mount. The advantages of OSOM are that it is CLIA waived and faster than the Affirm test and it has shown to be reliable compared with NAAT diagnosis of trichomoniasis.
Human Immunodeficiency Virus
There is a growing epidemic of HIV among adolescents and young adults in the United States. A recent study estimated that there were 56,000 new HIV infections in the United States in 2006, which corresponds to an estimated incidence rate of 22.8 per 100,000 population. 39 Because of the urgency of diagnosis and the difficulty in achieving follow-up for those who are tested, several POC tests have been developed. These include OraQuick, Reveal, Multi Spot, Uni-Gold, and Clearview. Because independent clinical trials for POC HIV tests require large sample sizes and expensive confirmatory testing, many of the studies evaluating test performance were submitted to the FDA and thus can be found in product inserts but not very often in peer-reviewed literature.
OraQuick Rapid HIV-1/2 Antibody Test (OraSure Technologies, Bethlehem, Pa) is an FDA-approved rapid test that can by used with whole blood and oral fluid specimens and plasma. It is considered a CLIA waived test when used with whole blood or oral fluids and is categorized as moderately complex when used with plasma. For blood and plasma, a specimen loop is used to transfer the samples to the test developer solution kit. For oral samples, the absorbent pad on the end of the test device is moved along the outer surface of the upper and lower gums and then inserted into a test vial. The test result can be read between 20 and 40 minutes. Like a pregnancy test, 2 lines (control and test lines) indicate a positive result, and 1 line (control only) is read as a negative result. 27 
Huppert et al
In the product literature, OraQuick is reported to be 99.3% sensitive for oral specimen, 99.6% for plasma, and 99.6% for finger-stick whole blood. 40 The cited specificity are 99.8% for oral specimens and 99.9% for plasma; and specificity, 100% for finger-stick whole blood.
In peer-reviewed literature, Delaney et al 41 reported 4 different studies to evaluate the OraQuick test using whole blood and oral specimens (Table 4) . Enzyme immunoassay (EIA) and Western blot were the criterion standard references. Of 12,337 participants, EIA and Western blot results detected HIV in 2.7% (327 participants). OraQuick detected 326 positive results using whole blood and 324 using oral specimens, for a 99.7% sensitivity on whole blood specimens and a 99.1% sensitivity on oral specimens. It was 99.9% specific with whole blood specimens and 99.6% specific with oral specimens.
In a recent study in 2009, Holguín et al 42 evaluated the performance of OraQuick to detect antibodies in oral and sera/ plasma specimens from participants from Spain and South America who were infected with different HIV-1 subtypes. One hundred fifty-six serum/plasma specimens and 139 oral specimens from people who had previously tested positive for HIV-1 by serological tests were tested with OraQuick. OraQuick detected all the positive results in the serum/plasma specimens, regardless of HIV-1 subtype, for a sensitivity of 100%. For oral specimens, it detected 136 of the 139 positive results, also regardless of subtype, for a sensitivity of 97.8%.
In 2009, Stekler et al 43 reported a comparison of OraQuick with EIA or NAAT testing on oral or finger-stick specimens from men who have sex with men. Of 14,005 specimens, 328 (2.3%) were HIV antibody positive and 36 (0.3%) were positive for HIV using NAAT/antibody negative. Of the 6811 specimens screened with OraQuick, the rapid test detected 91% of the antibodypositive results and NAAT detected 80% of the positive results. The specificity was 99.96% with a PPV of 98.1% and an NPV of 99.4%. Surprisingly, OraQuick performed less well in this highrisk screening setting than was expected.
Reveal G3 Rapid HIV-1 Antibody test (MedMira, Inc, Halifax, Nova Scotia) is a POC cartridge test that is FDA cleared for use with serum or plasma. As such, it requires laboratory equipment (centrifuge) and refrigeration of reagents, rendering it moderately complex by CLIA standards. The package insert for it describes studies evaluating the sensitivity and specificity of the test. 44 One study used 483 serum samples from known HIV-1 antibodyYpositive patients and an additional 2914 serum samples from high-risk individuals (total serum specimens, 3397) and compared Reveal results with EIA and Western blot testing results. There were 606 positive HIV-1 results (18%) by Western blot. The sensitivity of the Reveal test was 605 (99.8%) of 606. To test the specificity of serum samples, 850 serum samples from previously screened HIV-1 antibodyYnegative patients were added to 2914 newly collected serum samples from high-risk individuals (n = 3764 specimens). Of these, 3639 were deemed true negatives by Western blot. Reveal detected 3608 of these true negatives for a specificity of 99.1% (Table 5 ).
In addition to testing of serum samples, the performance of Reveal was examined for plasma samples in product literature. 44 In the first study, plasma samples were collected from 397 patients who were positive for HIV-1 and 107 patients who had a clinical diagnosis of acquired immunodeficiency syndrome (n = 504 specimens). Of these, 499 were positive for HIV by Western blot. Reveal detected 498 of 499 for a sensitivity of 99.8%. To determine specificity, 1000 known HIV-negative samples plus 2011 samples from unscreened people from low-risk population made up a sample size of 3011. Using Western blot to define a true negative, Reveal detected 2970 of the 3011 true negatives for a specificity of 98.6% (Table 5) . 44 Reveal G3 is FDA-cleared and rated as moderately complex.
Multispot HIV-1/HIV-2 Rapid Test (Bio-Rad Laboratories, Redmond, Wash) is another HIV rapid test. Like Reveal, it is FDA cleared for serum or plasma, requires equipment, and is moderately complex. According to the company's product sheet, 45 Multispot has 100% sensitivity for HIV-1 and HIV-2 compared with Western blot, and the specificity is 99.93% in fresh serum and 99.91% in fresh plasma. In the published literature, Phillips et al, 46 Multispot was tested on 241 serum samples, 172 of which were positive for HIV by Western blot and repeatedly reactive on EIA (prevalence, 71%). Multispot detected all infections correctly (positive and negative results), for a specificity of 100% and a sensitivity of 100%, regardless of HIV-1 subtype. Holguín et al 47 evaluated the performance of 3 rapid HIV tests, including Multispot. One hundred eleven plasma specimens were collected from African immigrants attending 3 HIV clinics in Spain. Of 48 frozen serum samples from 248 known subjects positive (by EIA reactivity and Western blot) for HIV were tested using Multispot. Multispot was able to detect all HIV-positive patients, for a sensitivity of 100% (Table 4) .
Multispot can be used with fresh or frozen serum or plasma. It is FDA approved and classified as moderately complex by CLIA. It requires 10 steps and takes approximately 9 minutes to complete. A negative result is when only the control spot appears (a purple spot in the top left corner). One, 2, or 3 extra spots in addition to the control spot indicate a positive result, and the spots indicate if it is HIV-1 or HIV-2. If there is no control spot at all, the test is invalid. 45 Uni-Gold Recombigen HIV test (Trinity Biotech PLC, Dublin, Ireland), according to the package insert, 49 in a study with 1032 specimens positive for HIV using Western blot, detected all specimens with positive test results when tested using the serum, plasma, and whole blood portions of the sample sets. Thus, the sensitivity was 100%. Two studies on the package insert evaluated specificity in both low-and high-risk groups. In the first study, of 1000 samples negative for HIV using EIA from a low-risk population, only 2 serum/plasma and 3 whole blood samples tested false positive using Uni-Gold, for specificities of 99.8% for serum or plasma and 99.7% for whole blood. Similar results were obtained using 968 samples negative for HIV using EIA from a high-risk population. Uni-Gold showed specificities of 99.7% for serum and 99.8% for plasma or whole blood in a high-risk population.
In contrast to other studies, Uni-Gold has been tested as an HIV screening tool. Eller et al 50 tested 940 whole blood samples from patients at a Ugandan blood bank. There were 10 HIVpositive samples using EIA, for a prevalence of 1.06%. Uni-Gold detected all samples with positive test results, for a sensitivity of 100%, and yielded 8 false-positive results, for a specificity of 99.1% (Table 4) .
Uni-Gold Recombigen HIV test (Trinity Biotech plc, Dublin, Ireland) is FDA approved and available for use in the United States. It can be used with whole blood, serum, or plasma. It is CLIA waived for use with whole blood and considered moderately complex when used with serum or plasma. It is easy to conduct and takes approximately 10 steps. 49 To perform, a sample of whole blood, serum, or plasma is collected with a pipette, and 1 drop is added on the sample port on the test device. Then 4 drops of the wash solution from the dropper bottle is added to the sample port. Results appear after 10 minutes. Like the OraQuick, a positive result is 2 lines (control and test lines), and a negative result is 1 line (control line only). 27 The package insert for Clearview HIV 1/2 Stat-Pak (Inverness, Princeton, NJ) reports data demonstrating the product's sensitivity and specificity. 51 For a sample of 1389 specimens (613 known positives and 776 from high-risk individuals), 647 were determined to be true HIV-1 positives by Western blot and/or FDA-approved NAAT assay (prevalence, 47%). The sensitivity of Clearview was 99.7%. In a sample of 203 true HIV-2 positives only (from serum/plasma specimens), the sensitivity was 100%. To determine specificity, 1431 specimens from high-and low-risk populations for HIV-1 were confirmed as a true negative by Western blot, immunofluorescence assay, or NAAT. The specificity of Clearview was 99.9%.
Clearview HIV 1/2 Stat-Pak is a simple, 2-step procedure used for whole blood (finger-stick or venipuncture), serum, or plasma. It is FDA approved, CLIA waived for use with whole blood, and classified as moderately complex for serum and plasma. Results are available in 15 minutes. This assay detects HIV-1 and HIV-2 for a complete picture in 1 test, and a minimal sample size of 5 KL reduces sample handling and exposure risk; it is less invasive for the patient. 51 A recent modification of this test is the Clearview Complete HIV 1/2 test, a single-use, self-contained, closed system for the collection processing and analysis of a whole blood, serum, or plasma sample for the detection of HIV-1 and HIV-2 antibodies. According to the package insert, Clearview Complete was tested against the same samples and yielded the same results as those described previously for Clearview Stat-Pak. 52 The added advantage of this system is its self-contained nature, which reduces the risk of exposure to health care workers.
In summary, the documented sensitivities and specificities of these various rapid HIV tests are exceptional. Of concern, however, is that published sensitivities may be less in clinical screening settings than expected, and antibody tests may miss early HIV infection that would be detected by NAAT, as was evidenced in the work of Steckler et al. 43 It is important for rapid HIV tests to be not only noninvasive (such as with oral specimens) and fast to encourage use and acceptance but also easy to read for clinicians. In this respect, the Multispot might not be best for a fast-paced clinical setting where there is not much time for interpretation and where physicians need something very simple to read.
The WHO and ASSURED Criteria
The ideal screening test for STIs would be 100% sensitive and 100% specific. However, few tests are perfect. The WHO launched an STI Diagnostics Initiative in 1990. 53 The current priorities of this initiative are to improve the detection of Chlamydia (screening of a high-risk population), gonorrhea (supporting syndromic management in highY and lowYdisease prevalence settings), and syphilis (specifically the screening of pregnant women). In conjunction, the initiative promoted the development and evaluation of STI diagnostics that meet specific criteria known by the acronym ASSURED. ASSURED stands for affordable by those at risk for infection, sensitiveVfew false negatives, specificVfew false positives, user-friendlyVsimple to perform (3Y4 steps required with minimal training necessary), rapid and robustVto enable treatment at first visit (rapid) and does not require refrigerated storage (robust), equipment-freeVeasily collected noninvasive specimens (eg, saliva and urine), and deliveredVto end users. 54 Based on these guidelines, we developed a scoring system for each criterion, assigning a higher value to indicate a better match. Thus, we rated affordability (cost to purchase a single test) as 0 (9$25), 1 ($11Y$24), 2 ($3Y$10), or 3 (G$2). Sensitivity and specificity were each scored as 0 (G65%), 1 (66%Y85%), 2 (83%Y94%), or 3(995%). Userfriendly scores related to CLIA designation are as follows: 0 (moderate complexity) or 1 (waived). Rapid and robust was scored as 0 (920 minutes to perform and/or refrigeration required) or 1 (G20 minutes to perform and requires no refrigeration). Equipment-free was scored on invasiveness of testing: 0 (major invasive sample, such as blood draw or pelvic examination), 1 (minor invasive sample, such as finger-stick), or 2 (noninvasive sample such as oral or vaginal swab or urine test). Delivered was determined by FDA clearance and availability for purchase in the United States and rated as 0 (not FDA cleared/available) or 1 (FDA cleared/available for sale). Criteria scores were summed (range, 0Y15). In Table 6 , we offer our opinion as to how well currently available POC tests would fare if judged by the ASSURED criteria using this scoring system.
Rationale Behind POC Tests for STIs
The ASSURED criteria also emphasize the benefits of POC testing. Point-of-care testing allows for quick and noninvasive Explanation of scores (total score is the sum [range, 0Y15]): Affordability (cost to purchase a single test): 0 (9$25), 1 ($11Y$24), 2 ($3Y$10), or 3 (G$2). Sensitivity and specificity: 0 (G65%), 1 (66%Y85%), 2 (83%Y94%), or 3 (995%). User-friendly 0 (moderate complexity) or 1 (waived). Rapid and robust: 0 (920 minutes to perform and/or refrigeration required) or 1 (G20 minutes to perform and requires no refrigeration). Equipment-free: 0 (major invasive sample, such as blood draw or pelvic examination), 1 (minor invasive sample, such as finger prick), or 2 (noninvasive sample, such as oral or vaginal swab or urine test).
Delivered: 0 (not FDA cleared/available) or 1 (FDA cleared/available for sale). *After initial outlay of more than $10,000 for machinery. NA indicates prices not available on the Web site.
ways to detect infection. Noninvasive tests are tests that do not require a pelvic examination, such as self-obtained vaginal or oral swabs or urine tests. Some patients find the pelvic examination uncomfortable, and some providers who care for young adults lack the resources and experience to perform a pelvic examination. 55 In fact, when participants were asked about acceptability of selfcollecting vaginal swabs to be used for rapid testing (in this case, for Chlamydia), 95.9% felt comfortable collecting self-swabs. 11 In addition, rapid POC STI tests allow the patient to have confidential notification and immediate treatment. This decreases the potential for disease spread, and the provider can offer immediate counseling on risk reduction actions such as abstinence and condom use.
Although an ideal POC test has near 100% sensitivity, this level of performance has not yet been achieved for most STIs (the exception is HIV). However, disease spread can be reduced even without perfect sensitivity. This crucial aspect of POC testing was highlighted by Gift et al. 56 Their analyses showed that a POC test that was 65% sensitive treated more Chlamydia-positive patients than the PCR alone if the return for treatment rate was less than 65%. Furthermore, Gift et al discovered that, Ba two-test algorithm of the rapid test followed by a PCR test on those initially testing negative identified and treated the greatest number of chlamydial infections and was the most cost-effective at all prevalences above 9%.[ The most important conclusion that can be drawn from the Gift et al study is that in situations where it is difficult to get patients to return for results and treatment, such as with adolescents, an imperfect POC test can help detect and treat a great portion of infections.
Patients like getting same-day results and are willing to wait for these results. More than 99% of participants in the study by Yin et al 8 indicated they were willing to wait up to 2 hours for rapid Chlamydia test results. Benzaken et al 16 also measured patient acceptability for a rapid gonorrhea test, and 98.8% of participants said they would be willing to wait up to an hour for test results. In reality, however, Bandea et al 5 found that 6.8% of patients would not wait more than 20 minutes for a POC Chlamydia test.
Point-of-care tests can also be used in series to increase sensitivity of testing. The study by Pattullo et al 31 describes a stepwise algorithm to improve detection of trichomoniasis. In this case, the inexpensive first test (wet mount) was 58% sensitive; adding a POC T. vaginalis test after a negative test result using wet mount increased sensitivity to 86%; and adding culture if the rapid test result was negative increased sensitivity to 94%. A similar algorithm could be applied to other STIs.
Barriers to Use of POC Tests in Clinical Settings
Barriers to use for POC tests in clinical settings include patient acceptability, clinician knowledge and acceptance, cost, and technology requirements. Patient acceptability of POC tests is just beginning to be explored. Although patients might be comfortable collecting self-swabs, they might not trust the results of the POC test as much as they would a standard testing method such as NAAT testing of samples from a pelvic examination or urine specimen. 57 Clinicians may sometimes fail to adopt new technologies and prefer testing methods they are comfortable with and are considered the criterion standard (ie, wet mount for trichomoniasis and NAAT for Chlamydia). There can be a wide variation in the time between product development and adoption of new technology, which depends not only on the costs of the new technology but also on how well information and support is distributed over the network of potential users. 58 Knowledge alone is not enough to ensure diffusion. A good example of the gap between knowledge and practice is the imperfect uptake of annual Chlamydia screening. Despite strong recommendations by scientific groups such as the CDC since 1993, in 2007, less than 50% of eligible women were screened for Chlamydia.
59Y61 Therefore, although developers work at building a better POC test that meets most of the ASSURED criteria, additional work will be required to ensure that these products are delivered to the end uses and do not languish on the shelves.
Potential Uses in Nonclinical Settings
In addition to the clinical context, POC tests have numerous potential uses in nonclinical settings such as schools, specifically outreach programs at schools that have medical supervision available, and homes, where the test can be purchased over the counter and performed without medical supervision. In the future, POC tests could be ordered on the Internet and delivered in the mail to maintain complete confidentiality for the user. Internet-delivered tests are useful for detecting infections in the community. 62 However, steps must be taken to ensure the quality of tests that are available via the Internet. One study showed that an approved Internet home Chlamydia test in the UK was less than 20% sensitive compared with NAAT. 63 
Future Directions
Several reliable POC tests are now on the market for clinical use for HIV and trichomoniasis. Available tests for Chlamydia have disappointing sensitivity, whereas tests for gonorrhea show promise in early studies. In the future, new POC tests need to meet the ASSURED criteria, including adequate sensitivity and specificity and a simple and rapid format, if the goal is to have clinicians adopt these new tests in busy clinical settings. Patients need to be educated on the benefits of POC tests and encouraged to wait for the results. If POC tests are used in nonclinical settings, measures will have to be in place to assure follow-up of results. If POC tests become available over the Internet or over the counter, patients, especially adolescents, may require additional incentives that encourage them to seek care after testing themselves. For example, Shew et al 64 showed that many adolescents who use a home pregnancy test do not seek medical attention after the testValthough presumably they are at continued risk for pregnancy, not to mention STIs. In addition, in an Internet study by Gaydos et al, 62 only one third of requested kits were returned for testing. If kits had contained a home test, it is unclear if some women would have failed to test themselves or neglected to get follow-up care.
What Is the Point?
There are many critical points about POC STI testing that argue for continued development and implementation of these tools. First, we must guard against the dissemination of inaccurate tests that will decrease clinician and patient acceptance of other new tests. If we are armed with POC tests that meet the ASSURED criteria, we can rapidly offer accurate and efficient tests to patients so that effective and immediate care can be offered. This will reduce the risks of disease sequelae in the individual patient, and transmission to partners can be prevented. Inexpensive and noninvasive tests will increase the likelihood that more people will be tested by a POC test than a traditional test. Thus, even imperfectly sensitive POC tests can be expected to dramatically impact the epidemic of STIs that exist in the United States today.
